Top Medical News
Too much animal-based protein poses increased AD risk
Jairia Dela Cruz, 3 days ago
Frequent intake of high-protein foods in diets, especially those derived from animals, appears to be associated with an increased risk of atopic dermatitis (AD) and allergic sensitization to common house dust mites, according to a study.
Chronic wounds cost Singapore 0.07% of GDP
Jairia Dela Cruz, 5 days ago
Chronic wounds impose a substantial economic burden on Singapore, costing the country approximately 0.07 percent of its gross domestic product (GDP) annually, as reported in a study.
Dupilumab beneficial in treatment of bullous pemphigoid
24 Sep 2023
Treatment with dupilumab appears to be safe and effective in the treatment of patients with bullous pemphigoid (BP), yielding significant improvements in symptoms with a favourable safety profile, according to a study.
Does UV-B phototherapy increase the risk of skin cancer in AD patients?
18 Sep 2023
Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.
Bimekizumab safe, effective in moderate-to-severe plaque psoriasis
Stephen Padilla, 18 Sep 2023
The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.
Atopic dermatitis linked to subsequent IBD
05 Sep 2023
Children and adults with atopic dermatitis (AD) are at risk of inflammatory bowel disease (IBD), with the risk varying by age, AD severity, and IBD subtype, according to a study.
Jakinibs for AD in Asians: Is one better than the other?
Elvira Manzano, 31 Aug 2023
Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis  (AD) as shown in an Asian retrospective cohort study.
Special Reports
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Conference Reports
Jakinibs for AD in Asians: Is one better than the other?
Elvira Manzano, 31 Aug 2023
Treatment with oral Janus kinase (JAK) inhibitors or jakinibs appeared well tolerated in patients with atopic dermatitis  (AD) as shown in an Asian retrospective cohort study.
Abrocitinib effectively controls AD regardless of dosing regimen
Audrey Abella, 03 Aug 2023
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Dupilumab confers benefit in bullous pemphigoid
Audrey Abella, 02 Aug 2023
The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.
Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis
Elaine Soliven, 01 Aug 2023
Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.
Integrated analysis supports long-term efficacy of ritlecitinib for alopecia areata
Audrey Abella, 28 Jul 2023
An integrated analysis of the pivotal phase IIb/III ALLEGRO and phase III ALLEGRO-LT studies demonstrated the long-term efficacy of the oral JAK3/TEC family kinase inhibitor ritlecitinib for alopecia areata (AA).
Nemolizumab relieves itch, clears skin in patients with prurigo nodularis
Elaine Soliven, 27 Jul 2023
Treatment with nemolizumab significantly improves itch and skin clearance in patients with prurigo nodularis compared with placebo, according to the phase III OLYMPIA 2 trial presented at WCD 2023.
Platelet-rich fibrin matrix shows promise for trophic ulcers
Jairia Dela Cruz, 12 Jul 2023
Platelet-rich fibrin matrix (PRFM) compares favourably with platelet-rich plasma (PRP) in the treatment of chronic trophic ulcer associated with leprosy, as shown in the results of an observer-blind, noninferiority randomized controlled trial.